A cure for certain cancers could be a realistic goal within the next decade, according to Johnson & Johnson Chairman and CEO Joaquin Duato. During the WSJ Leadership Institute CEO Summit in London, Duato outlined projections for the future of cancer treatment, stating that the company's objective is to "try to eliminate cancer" in the coming 10 years.
Duato highlighted significant progress in specific cancer types, pointing to multiple myeloma as an example where advancements in immunotherapy have dramatically improved patient outcomes. He noted that treatments utilizing the patient's own immune system have achieved remarkable results, with some patients who were previously nearing hospice care remaining in remission for over five years after a single administration of therapy.
"We have treatments now that utilize your own immune system to attack the cancer," Duato said. "For patients who were already going into hospice, so they didn’t have any other alternative, they are [at] more than five years, with a single administration, in remission. That [is] spectacular."
He predicted that while some cancers may be cured entirely, others will be managed as chronic diseases. Johnson & Johnson is focusing on understanding cancer biology and developing new technologies to combat the disease. Duato also commented on the potential of artificial intelligence in healthcare, calling it a "force multiplier" that can aid in earlier diagnosis and more personalized surgical approaches.
Fox News senior medical analyst Dr. Marc Siegel concurred with Duato's optimistic outlook. Siegel suggested that future advances will rely on AI to guide targeted treatments, informed by expanding knowledge of cancer mutations and how to target them. He added that biomarkers and AI can facilitate earlier diagnoses and more advanced, personalized surgery. Johnson & Johnson recently acquired Firefly Bio, a company developing drugs designed to target specific proteins within cancer cells that harbor difficult-to-treat gene mutations.